My question relates to the Novavax vaccine, which may be available in the US in 2022. It will probably be safer in terms of initial adverse reactions than the mRNA/viral vector vaccines that cause the body to produce the spike protein...as there is a fixed amount of spike protein used in Novavax from my understanding. However, Novavax is still centered around the spike protein, so would it potentially have the same risk of ADE? Thank you.
Have you investigated Chlorine Dioxide taken orally as a mechanism to selectively oxidize the virus? 5000 doctors in 25 countries used it to for the treatment of Covid-19 today: https://keithcu.com/wordpress/?p=4084
Is there any where that Geert talks specifically what individuals should do? I'm already 'vaccinated'. Should I get the boosters or not? If I don't will this eventually allow my innate immunity to take over again & possibly win the day for me OR because I'm already vaxxed should I stay on the booster treadmill because my innate immunity has been supplanted by my vaxxed immunity?
Would the short lived Spike protein directed Antibodies interfere with vaccine generated antibodies in the first few weeks into the first vaccination dose? Would this be functionally different for a vaccine aimed at the spike protein itself vs whole inactivated type of vaccine (which has a non-zero chance of improper inactivation and inadvertent infection). Would the interaction between these two different types of immune responses, mass induced in a population rapidly help the virus figure out how to evade innate immune defenses?
I ask this because countries like Chile and India also used inactivated whole virus vaccines (in India they utilized both the spike protein based Astrazeneca and Covaxin which was whole inactivated virus which in their recently released trials results showed a 70% higher SARS-CoV-2 infection rate compared to placebo before the second dose).
These countries appear to show a different kind of trajectory likely as the virus encountered all four types of immune statuses - naive-innate, infection-adaptive, vaccinal-spike, short lived spike directed antibodies.
My question relates to the Novavax vaccine, which may be available in the US in 2022. It will probably be safer in terms of initial adverse reactions than the mRNA/viral vector vaccines that cause the body to produce the spike protein...as there is a fixed amount of spike protein used in Novavax from my understanding. However, Novavax is still centered around the spike protein, so would it potentially have the same risk of ADE? Thank you.
Have you investigated Chlorine Dioxide taken orally as a mechanism to selectively oxidize the virus? 5000 doctors in 25 countries used it to for the treatment of Covid-19 today: https://keithcu.com/wordpress/?p=4084
Is there any where that Geert talks specifically what individuals should do? I'm already 'vaccinated'. Should I get the boosters or not? If I don't will this eventually allow my innate immunity to take over again & possibly win the day for me OR because I'm already vaxxed should I stay on the booster treadmill because my innate immunity has been supplanted by my vaxxed immunity?
Thank you so much for your voice of reason amidst these dark days! Michele Klemetson
Dr. James Lyons-Weiler & Dr. David Martin explain the whole enchilada ... https://vrevealed.com/c19/viewing
Dear Dr. Vanden Bossche,
Would the short lived Spike protein directed Antibodies interfere with vaccine generated antibodies in the first few weeks into the first vaccination dose? Would this be functionally different for a vaccine aimed at the spike protein itself vs whole inactivated type of vaccine (which has a non-zero chance of improper inactivation and inadvertent infection). Would the interaction between these two different types of immune responses, mass induced in a population rapidly help the virus figure out how to evade innate immune defenses?
I ask this because countries like Chile and India also used inactivated whole virus vaccines (in India they utilized both the spike protein based Astrazeneca and Covaxin which was whole inactivated virus which in their recently released trials results showed a 70% higher SARS-CoV-2 infection rate compared to placebo before the second dose).
These countries appear to show a different kind of trajectory likely as the virus encountered all four types of immune statuses - naive-innate, infection-adaptive, vaccinal-spike, short lived spike directed antibodies.